Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


26.02.2024

1 Am J Clin Pathol
1 Am J Surg Pathol
2 Blood
2 Br J Dermatol
2 Eur J Haematol
3 Haematologica
1 J Biol Chem
5 Leuk Lymphoma
2 Leukemia


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. SHEN Z, Wang Y, Xie R, Zhang Q, et al
    Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma.
    Am J Clin Pathol. 2024 Feb 22:aqae012. doi: 10.1093.
    PubMed         Abstract available


    Am J Surg Pathol

  2. LIBERT D, Zhao S, Younes S, Mosquera AP, et al
    TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
    Am J Surg Pathol. 2024;48:337-352.
    PubMed         Abstract available


    Blood

  3. ANG Z, Thomas-Tikhonenko A
    Lymphoma immunotherapy: the garden of forking paths.
    Blood. 2024;143:655-657.
    PubMed        

  4. SCHOOLCRAFT DK, Karrs JX
    Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
    Blood. 2024;143:738.
    PubMed        


    Br J Dermatol

  5. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
    Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
    Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
    PubMed        

  6. JUNG JM, Cho HS, Kim GH, Won CH, et al
    Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
    Br J Dermatol. 2024;190:432-434.
    PubMed        


    Eur J Haematol

  7. HEGER JM, d'Hargues Y, Kleinert F, Mattlener J, et al
    Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Eur J Haematol. 2024 Feb 18. doi: 10.1111/ejh.14191.
    PubMed         Abstract available

  8. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    PubMed         Abstract available


    Haematologica

  9. STATHIS A, Pirosa MC, Orsucci L, Feugier P, et al
    IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918.
    PubMed         Abstract available

  10. MARTIRE G, Lovisa F, Carraro E, Rizzato D, et al
    TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868.
    PubMed         Abstract available

  11. DURAND R, Bellanger C, Kervoelen C, Tessoulin B, et al
    Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284345.
    PubMed         Abstract available


    J Biol Chem

  12. LIU C, Zhao X, Wang Z, Zhang C, et al
    LncRNA CHROMR/miR-27b-3p/MET axis promotes the proliferation, invasion and contributes to rituximab resistance in diffuse large B-cell lymphoma.
    J Biol Chem. 2024 Feb 15:105762. doi: 10.1016/j.jbc.2024.105762.
    PubMed         Abstract available


    Leuk Lymphoma

  13. WEI C, Zhai F, Jia C, Zhang W, et al
    Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma.
    Leuk Lymphoma. 2024 Feb 22:1-4. doi: 10.1080/10428194.2024.2316252.
    PubMed        

  14. TASHAKORI M, Medeiros LJ
    Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms.
    Leuk Lymphoma. 2024 Feb 21:1-5. doi: 10.1080/10428194.2024.2319691.
    PubMed         Abstract available

  15. NEMEC R, Scherrer-Crosbie M, Abramson JS, Redd R, et al
    Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
    Leuk Lymphoma. 2024 Feb 21:1-6. doi: 10.1080/10428194.2024.2317343.
    PubMed         Abstract available

  16. BAGGIO D, Wellard C, Chung E, Talaulikar D, et al
    Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
    Leuk Lymphoma. 2023;64:621-627.
    PubMed         Abstract available

  17. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    PubMed        


    Leukemia

  18. CHEN Z, Huang H, Huang H, Yu L, et al
    Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
    Leukemia. 2024 Feb 20. doi: 10.1038/s41375-024-02171.
    PubMed         Abstract available

  19. HOLMQVIST AS, Meng Q, Dai C, Hageman L, et al
    Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02144.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.